AI-Assisted TelerehabiLitAtion System (ATLAS) for Post-discharge Continuation of Rehabilitative Care
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-99
SponsorSingHealth Community Hospitals
About this trial
The study team proposes ATLAS (AI-Assisted TelerehabiLitAtion System) a two-part solution. The first-Rebee AI-assisted telerehabilitation device-assists in inpatient rehabilitation, and allows patients to continue with their physical rehabilitation when discharged and waiting for Day Rehabilitation Centre (DRC). The second-a structured programme to train and familiarise patients and caregivers to Rebee over patients' Community Hospital (CH) inpatient rehabilitation stay-adopts an evidence-based approach to increase uptake and adherence to Rebee.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Rehabilitation Diagnostic Group (RDG): Total Knee Replacement / Deconditioning
Age 60 and above
Speak English/Mandarin
Able to follow instructions, no cognitive impairment
Disqualifiers
Not under RDG: Total Knee Replacement / Deconditioning
Below 60 years old
Unable to speak English/Mandarin
Cognitive impaired, unable to follow instructions
Trial design
Design model
Parallel
Treatments tested in this trial
Rebee
DeviceTablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge
Treatment groups
450 Participants
are divided into 2 treatment groupsGroup A: Control - usual careNo intervention 0 interventions
Group B: Intervention - RebeeExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in Modified Barthel Index scores from baseline to 4, 8, and 12 weeks
Modified Barthel Index (MBI) measures ability to complete activities of daily living (ADLs). Scores range from 0 to 100. A higher score represents more independence, a lower score indicates more assistance needed (ie less independent). 0-20: Total dependence, 21-60: Severe dependence, 61-90: Moderate dependence, 91-99: Slight dependence, 100: Independence.
Time frame
from recruitment (week 0) till end of study at 12 weeksSecondary outcomes
1
Change in Quality of Life scores from baseline to 4, 8, and 12 weeks
Quality of Life as measured using EQ-5D-5L. Has two components to this instrument: 1. EQ-5D descriptive system * 1 to 5 for each dimension * A higher score represents "worse health status" (i.e., more severe problems with dimension). 2. EQ visual analogue scale (EQ VAS) * 0 to 100 * A higher score represents "better health status" (i.e., overall current health status).
Time frame
from recruitment (week 0) till end of study at 12 weeks2
Change in Patient Activation Level from baseline to 4, 8, and 12 weeks
Patient Activation Level measured using PAM-13 Score from 0 to 100 Higher scores indicate greater patient activation
Time frame
from recruitment (week 0) till end of study at 12 weeks3
Readmission rates to hospital within 30 days of discharge
e.g. 0 means no readmissions back to hospital within 30 days of discharge occured
Time frame
within 30 days from discharge date4
Change in Joint range of motion from baseline to 4, 8, and 12 weeks
Measured Joint Range of operated knee for patients with total knee replacement (TKR) Joint range will be measured for knee Extension and well as knee Flexion
Time frame
from recruitment (week 0) till end of study at 12 weeksLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
SingHealth Community Hospitals
Lead sponsor
Rebee Health
Collaborator
Jurong Community Hospital
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: